AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.

Wang X, Zhang S, Wang Q, Leng J, Zhang M, Wan G, Zhu Y, Huang B, Ran J

Open source

DOI
10.1007/s11011-026-01985-8
Published
2026 Sep 12
Container
Metabolic brain disease
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11011-026-01985-8,
  title = {AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.},
  author = {Wang X and Zhang S and Wang Q and Leng J and Zhang M and Wan G and Zhu Y and Huang B and Ran J},
  year = {2026},
  journal = {Metabolic brain disease},
  doi = {10.1007/s11011-026-01985-8},
  url = {https://doi.org/10.1007/s11011-026-01985-8}
}

RIS

TY  - JOUR
TI  - AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.
AU  - Wang X
AU  - Zhang S
AU  - Wang Q
AU  - Leng J
AU  - Zhang M
AU  - Wan G
AU  - Zhu Y
AU  - Huang B
AU  - Ran J
PY  - 2026
JO  - Metabolic brain disease
DO  - 10.1007/s11011-026-01985-8
UR  - https://doi.org/10.1007/s11011-026-01985-8
ER  - 

APA

X, W., S, Z., Q, W., J, L., M, Z., G, W., Y, Z., B, H., & J, R. (2026). AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.. Metabolic brain disease. https://doi.org/10.1007/s11011-026-01985-8

Source records